All In Biotech

NDA 020675 · Abbvie

Urso 250

Ursodiol · Oral · Bile Acid

OrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Jan 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Dec 10, 1997

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

202

58 Phase 3, 24 recruiting

FAERS reports

22,309

17,866 serious, 3,055 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 12, 2023.

URSO 250 and URSO Forte (ursodiol) tablets are indicated for the treatment of patients with primary biliary cholangitis (PBC). URSO 250 and URSO Forte (ursodiol) tablets are bile acids indicated for the treatment of patients with primary biliary cholangitis. ( 1 )

Mechanism: Ursodiol, a naturally occurring hydrophilic bile acid, derived from cholesterol, is present as a minor fraction of the total human bile acid pool. Oral administration of ursodiol increases this fraction in a dose related manner, to become the major biliary acid, replacing/displacing toxic concentrations of endogenous hydrophobic bile acids that tend to accumulate in cholestatic liver disease. In addition to the replacement and displacement of toxic bile acids, other mechanisms of action include cytoprotection of the injured bile duct epithelial cells (cholangiocytes) against toxic effects of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service returned an error (500). The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Ursodiol" as an intervention, any sponsor and status, largest first.

All 202 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,842
  • pruritus1,326
  • diarrhoea1,284
  • fatigue1,129
  • nausea1,091
  • pyrexia1,016
  • drug ineffective987
  • pneumonia791
  • death730
  • vomiting714
  • headache647
  • dyspnoea609

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Urso Forte (Ursodiol)

2024 spending

$29K

Beneficiaries

19

25 claims

Per beneficiary

$1,535

$9.28 per unit

View as table
YearSpending
2020$558,871
2021$526,474
2022$499,669
2023$391,797
2024$29,161

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 42 on PubMed

Sponsor: AbbVie · Also marketed as Urso Forte

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.